RX-518 manufacturers
- RX-518
-
- $0.00 / 1kg
-
2025-04-04
- CAS:1660963-42-7
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
- EGFR-IN-3
-
- $397.00 / 1mg
-
2024-11-19
- CAS:
- Min. Order:
- Purity: 98.1%
- Supply Ability: 10g
- Olafertinib
-
- $41.00 / 1mg
-
2024-11-19
- CAS:1660963-42-7
- Min. Order:
- Purity: 98.43%
- Supply Ability: 10g
|
| Product Name: | RX-518 | | Synonyms: | RX-518;N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide;N-[3-[2-[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]quinazolin-8-yl]phenyl]prop-2-enamide;EGFR-IN-3;RX518(CK-101);CK 101;CK101;CK-101 | | CAS: | 1660963-42-7 | | MF: | C29H28F2N6O2 | | MW: | 530.57 | | EINECS: | | | Product Categories: | | | Mol File: | 1660963-42-7.mol |  |
| | RX-518 Chemical Properties |
| density | 1.350±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 125 mg/mL (235.60 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | pka | 13.28±0.70(Predicted) | | color | Light yellow to yellow |
| | RX-518 Usage And Synthesis |
| Uses | Olafertinib is a third-generation EGFR TKI, with GI50 values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. Olafertinib has the potential for NSCLC research[1]. | | References | [1] Misako Nagasaka, et al. Beyond osimertinib: The development of 3 rd-generation EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2020 Dec 15;S1556-0864(20)31105-9. DOI:10.1016/j.jtho.2020.11.028 |
| | RX-518 Preparation Products And Raw materials |
|